One Retrospective Cohort, One Prospective Cohort, in Total of ~2,400 Cancer Patients and Non-cancer Individuals Demonstrate the Performance of SeekInCare Test to Detect Multiple Cancer Types and Predict Tissue of Origin of Cancers

一个回顾性队列，一个前瞻性队列，总共约2400名癌症患者和非癌症个体证明了SeekInCare测试在检测多种癌症类型和预测癌症起源组织方面的表现

The Achievement of 65.5% Sensitivity at 97.9% Specificity in the Retrospective Study and 60.0% Sensitivity at 96.1% Specificity in the Prospective Study Places SeekInCare among the Best-in-Class in Non-invasive Multi-cancer Early Detection

在回顾性研究中达到65.5%的敏感性，特异性为97.9%，在前瞻性研究中达到60.0%的敏感性，特异性为96.1%，这使SeekInCare成为非侵入性多癌早期检测中一流的

SHENZHEN, China, Nov. 10, 2023 /PRNewswire/ -- SeekIn Inc., a leader in blood-based pan-cancer early detection and monitoring technology, today announced the validation studies consisting of one retrospective cohort and one prospective cohort that evaluate SeekInCare's ability to detect cancer patients and predict the tissue of origin with one tube of blood.

2023年11月10日，中国深圳/PRNewswire/-SeekIn公司是基于血液的泛癌早期检测和监测技术的领导者，今天宣布验证研究包括一项回顾性队列研究和一项前瞻性队列研究，评估SeekInCare检测癌症患者的能力，并用一管血液预测起源组织。

The results demonstrate the performance of SeekInCare with the consistent results among the two cohorts in ~2,400 cancer patients and non-cancer individuals. SeekInCare achieved overall 65.5% sensitivity at 97.9% specificity in the retrospective studies and 60.0% sensitivity at 96.1% specificity in the prospective cohort study, respectively, which is best-in-class in blood-based multi-cancer early detection (MCED).

结果表明SeekInCare的表现在约2400名癌症患者和非癌症个体的两个队列中具有一致的结果。SeekInCare在回顾性研究中以97.9%的特异性获得总体65.5%的敏感性，在前瞻性队列研究中分别以96.1%的特异性获得60.0%的敏感性，这在基于血液的多癌症早期检测（MCED）中是一流的。

The findings were presented at the 20th ICGC Workshop and 7th ARGO Meeting in New York..

调查结果在纽约举行的第20届ICGC研讨会和第7届ARGO会议上提出。。

'Recent studies have demonstrated that blood-based multi-cancer early detection approaches may hold promise for identifying asymptomatic cancer patients from general population. However, most studies only exploit a single aspect of cancer hallmarks, which is challenging to achieve highly sensitive results because cancer is a heterogenous disease,' said Mao Mao, MD, PhD, Founder and CEO of SeekIn.

最近的研究表明，基于血液的多癌症早期检测方法可能有望从普通人群中识别出无症状的癌症患者。然而，大多数研究仅利用癌症标志的一个方面，这对于实现高度敏感的结果是具有挑战性的，因为癌症是一种异质性疾病，“SeekIn的创始人兼首席执行官毛茂博士说。

'For example, our OncoSeek test for multi-cancer early detection was designed with seven protein tumor markers. With the assistance of artificial intelligence (AI), the sensitivity of OncoSeek was 51.7% at 92.9% specificity. While OncoSeek significantly reduced false positive rates comparing with traditional methods, we believe sensitivity can be further improved when more omics data are included.

“例如，我们的OncoSeek多癌症早期检测测试设计了七种蛋白质肿瘤标志物。在人工智能（AI）的帮助下，OncoSeek的敏感性为51.7%，特异性为92.9%。虽然OncoSeek与传统方法相比显着降低了假阳性率，但我们相信当包含更多组学数据时，灵敏度可以进一步提高。

And this is how SeekInCare was conceived.'.

这就是SeekInCare的构思方式。

SeekInCare was developed using proprietary AI- and big data-driven algorithm to distinguish cancer patients from non-cancer individuals by calculating cancer risk score (CRS) incorporating copy number aberrations (CNAs), fragment size (FS), end motifs and oncogenic viruses via shallow whole genome sequencing (sWGS) from cell-free DNA (cfDNA), and seven plasma tumor markers (PTMs), and to predict the possible affected tissue of origin (TOO) for those who have been detected with cancer signals in blood.

SeekInCare是使用专有的AI和大数据驱动算法开发的，通过计算包含拷贝数异常（CNA），片段大小（FS），末端基序和癌症的癌症风险评分（CRS），将癌症患者与非癌症患者区分开来。通过来自无细胞DNA（cfDNA）的浅全基因组测序（sWGS）和七种血浆肿瘤标志物（PTM）的致癌病毒，并预测那些在血液中检测到癌症信号的人可能受影响的起源组织。

SeekInCare's performance was well-demonstrated by the overall 65.5% sensitivity at 97.9% specificity in the retrospective study and 60.0% sensitivity at 96.1% specificity in the prospective study. A critical attribute of a blood-based multi-cancer detection test is the ability to localize the TOO to direct the diagnostic workup.

回顾性研究中97.9%特异性的总体65.5%敏感性和前瞻性研究中96.1%特异性的60.0%敏感性很好地证明了SeekInCare的表现。基于血液的多癌症检测测试的关键属性是能够定位以指导诊断检查。

The overall accuracy of two most possible organs SeekInCare achieved was 85.4%, improved by 20.0% from OncoSeek..

SeekInCare实现的两种最可能器官的总体准确率为85.4%，OncoSeek提高了20.0%。。

'In addition to the performance improvement of SeekInCare in TOO prediction comparing with OncoSeek, significant improvements were also observed in major metrics such as sensitivity, specificity and accuracy. Unlike OncoSeek designed for low- and middle-income countries, SeekInCare enables us to provide a more sensitive and specific multi-cancer detection solution to the regions with purchasing power and high demands of advanced cancer screening,' said Dr.

'除了与OncoSeek相比SeekInCare在太预测方面的性能改进之外，在敏感性，特异性和准确性等主要指标方面也观察到显着改善。与专为低收入和中等收入国家设计的OncoSeek不同，SeekInCare使我们能够为具有购买力和对先进癌症筛查高要求的地区提供更敏感和更具体的多癌症检测解决方案。

Mao. 'More importantly, comparing with the results of both retrospective and prospective studies from GRAIL and Exact Sciences, SeekInCare showed higher sensitivities with similar specificities.'.

毛更重要的是，与GRAIL和Exact Sciences的回顾性和前瞻性研究结果相比，SeekInCare显示出更高的敏感性和相似的特异性。

The excellent consistency of validation results from both retrospective and prospective studies established SeekInCare's clinical feasibility. With these achievements, SeekIn is planning for future investigation of SeekInCare's clinical utility as a large-scale cancer screening test in average-risk populations..

回顾性和前瞻性研究的验证结果具有极好的一致性，这确立了SeekInCare的临床可行性。凭借这些成就，SeekIn计划未来对SeekInCare作为平均风险人群中大规模癌症筛查测试的临床效用进行调查。。

About SeekIn

关于SeekIn

SeekIn Inc. is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing next-generation sequencing and artificial intelligence. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation.

SeekIn Inc.是一家生物技术公司，成立于2018年初，位于中国深圳，专注于利用新一代测序和人工智能进行基于血液的泛癌早期检测。自成立以来，SeekIn一直致力于为癌症早期发现，术后复发监测和治疗反应评估提供尖端且具有成本效益的解决方案。

SeekIn also developed novel molecular tests for leukemia patients. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in China. SeekIn envisions that, by leading a new norm for cancer early detection, the clinical outcome of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%.

SeekIn还为白血病患者开发了新的分子检测方法。凭借其专有的技术进步，SeekIn与中国顶级医院合作开展了多项研究和临床研究。SeekIn设想，通过领导癌症早期发现的新规范，中晚期癌症患者的临床结果可以逆转，癌症死亡率可以降低15%。

For more information about SeekIn's cutting-edge technologies and products, visit www.seekincancer.com..

有关SeekIn尖端技术和产品的更多信息，请访问www.seekincancer.com。。

About SeekInCare

关于SeekInCare

SeekInCare has been developed as a multi-cancer early detection (MCED) test that takes a panoramic view of blood cell-free cancer signatures and a multi-omics approach incorporating genomic and epigenetic alterations in conjunction with clinically validated protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare exhibits superior effectiveness to detect cancer at high specificity.

SeekInCare已被开发为一种多癌症早期检测（MCED）测试，可对无血细胞癌症特征进行全景观察，并采用多组学方法，将基因组和表观遗传改变与临床验证的蛋白质生物标志物结合起来。配备专有的AI和大数据驱动的CRS算法，SeekInCare在高特异性检测癌症方面表现出卓越的效果。

SeekInCare is intended to use for the individuals with elevated risks of cancer such as smoking, chronic hepatitis, aging, etc., in conjunction with the approved conventional single cancer type screening tests.SeekInCare is CE-IVD certified..

SeekInCare旨在与批准的常规单一癌症类型筛查测试一起用于癌症风险升高的个体，例如吸烟，慢性肝炎，衰老等。SeekInCare已通过CE-IVD认证。。

SOURCE SeekIn Inc

资料来源SeekIn Inc